BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...and January’s investment in the $230 million series B by Flagship Pioneering’s gene writing play Tessera Therapeutics Inc....
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...By Jeff Cranmer, Executive Editor Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230 million series...
Items per page:
1 - 2 of 2
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...and January’s investment in the $230 million series B by Flagship Pioneering’s gene writing play Tessera Therapeutics Inc....
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...By Jeff Cranmer, Executive Editor Flagship Pioneering Gene Writing company Tessera Therapeutics Inc. raised a $230 million series...
Items per page:
1 - 2 of 2